[Research progress of the application of regional citrate anticoagulation in artificial liver to treat liver failure].

Liver failure is a rapidly progressive condition with a high mortality rate. Artificial liver treatment is one of the most important treatments for liver failure. In order to ensure the smooth functioning of in vitro circulation device, anticoagulants such as heparin or low-molecular-weight heparin are often used in clinical practice. However, it induces hemorrhage, thrombocytopenia and other adverse reactions, thereby threatening the life safety of liver failure patients. Regional citrate anticoagulation does not affect the coagulation mechanism in vivo, nor does it effects platelets, so in vitro circulating anticoagulants has become the first choice anticoagulant treatment method for continuous renal replacement therapy. Combined with the current research condition at home and abroad, the research progress of the application of regional citrate anticoagulation in artificial liver to treat liver failure is discussed, covering its principle content, application status and application prospect.